Literature DB >> 6456563

Abdominal sepsis managed by leaving abdomen open.

J H Duff, J Moffat.   

Abstract

Intra-abdominal sepsis and necrotizing infection of the abdominal wall are usually fatal unless adequate drainage and wide debridement are possible. To follow these principles, we managed 18 seriously ill patients with abdominal sepsis by leaving the abdomen completely open. All except two of the patients had severe intra-abdominal sepsis. Eight patients had full-thickness wound infections and intra-abdominal infections refractory to the usual surgical drainage techniques. Two had necrotizing wound infections only. In 12 an upper abdominal incision was managed open, and in six the open incision was lower. As part of the initiating illness, there were eight small bowel and six colon fistulas. They were managed by colostomy in five patients and ileostomy in two. More than one organism was cultured in all patients and 12 of 18 had a positive blood culture. Respiratory failure made mechanical ventilation necessary in 13 patients for an average of 44 days. Previous adhesions, usually present, or an intact greater omentum, were necessary to prevent bowel evisceration, but three patients required paralysis and mechanical ventilation until adhesions became strong enough to prevent evisceration. There were seven deaths (39%), six caused by continuing sepsis and one from hemorrhage. In those surviving, granulation tissue grew over omentum or bowel loops to eventually seal the abdominal cavity. The late management was split-skin grafting in five and secondary closure in two. Four healed by second intention. We conclude that leaving the abdomen completely open facilitates the widest possible drainage, uncompromising debridement of the abdominal wall, and is compatible with good recovery. The ultimate result in survivors is acceptable. This technique is preferable to closing an abdominal wall of questionable viability in the face of intraperitoneal sepsis.

Entities:  

Mesh:

Year:  1981        PMID: 6456563

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  22 in total

1.  Staged abdominal repair for treatment of moderate to severe secondary peritonitis.

Authors:  Fatih Agalar; Erol Eroglu; Mahmut Bulbul; Canan Agalar; Omar Ridvan Tarhan; Mustafa Sari
Journal:  World J Surg       Date:  2005-02       Impact factor: 3.352

2.  Open abdomen management after massive bowel resection for superior mesenteric arterial occlusion.

Authors:  Kenji Mimatsu; Takatsugu Oida; Hisao Kanou; Hiroshi Miyake; Sadao Amano
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  Sequential abdominal reexploration with the zipper technique.

Authors:  M A Cuesta; M Doblas; L Castañeda; E Bengoechea
Journal:  World J Surg       Date:  1991 Jan-Feb       Impact factor: 3.352

4.  Enterocutaneous fistulas in the setting of trauma and critical illness.

Authors:  Joseph J Dubose; Jonathan B Lundy
Journal:  Clin Colon Rectal Surg       Date:  2010-09

5.  Intraabdominal infections--introduction.

Authors:  D H Wittmann
Journal:  World J Surg       Date:  1990 Mar-Apr       Impact factor: 3.352

6.  [Attempt at classification in patients with peritonitis--evaluation of 53 patients].

Authors:  G Hünefeld; N Friedel; R Pichlmayr
Journal:  Langenbecks Arch Chir       Date:  1986

7.  The zipper-mesh method for treating delayed generalized peritonitis.

Authors:  F Ercan; A Korkmaz; N Aras
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

8.  [Abdominal vacuum device with open abdomen].

Authors:  P Oetting; B Rau; P M Schlag
Journal:  Chirurg       Date:  2006-07       Impact factor: 0.955

9.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

10.  Fibrin in peritonitis. V. Fibrin inhibits phagocytic killing of Escherichia coli by human polymorphonuclear leukocytes.

Authors:  O D Rotstein; T L Pruett; R L Simmons
Journal:  Ann Surg       Date:  1986-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.